We conclude that regression patterns of tumors in patients undergoing systemic chemoreduction with focal adjuvant treatments predominantly changed over time and their changes are dependent on tumor size, location, and type of treatment. It appears that subretinal seeds, tumor size, and location of tumors are the most important factors predicting tumor recurrence.

In transepithelial PRK, refractive outcome depends little on preexisting corneal epithelial thickness. There is a concern about the contraction of OZ, especially in lower intended ablations.